Research and Markets: Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2013

Fri Jun 7, 2013 5:16am EDT

* Reuters is not responsible for the content in this press release.

Research and Markets: Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2013

Research and Markets (http://www.researchandmarkets.com/research/pmj88n/hospital_acquired) has announced the addition of the "Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2013" report to their offering.

Global Markets Direct's, 'Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hospital Acquired Pneumonia (HAP), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hospital Acquired Pneumonia (HAP).

Scope

- A snapshot of the global therapeutic scenario for Hospital Acquired Pneumonia (HAP).

- A review of the Hospital Acquired Pneumonia (HAP) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Hospital Acquired Pneumonia (HAP) pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- News and deals relating to the products.

Reasons to Buy

- Identify and understand important and diverse types of therapeutics under development for Hospital Acquired Pneumonia (HAP).

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.

- Devise corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

For more information visit http://www.researchandmarkets.com/research/pmj88n/hospital_acquired

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.